A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain
Phase 3
Terminated
- Conditions
- Bone NeoplasmNeoplasm MetastasisPain
- Interventions
- Registration Number
- NCT00099177
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This 2 arm study will compare the efficacy of a regimen of intravenous (iv) and oral Bondronat with that of zoledronic acid in patients with malignant bone disease experiencing moderate to severe pain. Patients will be randomized to receive either Bondronat (6mg iv on days 1, 2 and 3 followed by Bondronat 5Omg po daily from day 22 to week 24) or zoledronic acid (4mg iv on day 1, and then every 3-4 weeks). The anticipated time of study treatment is 6-12 months, and the target sample size is 100-500 individuals.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 96
Inclusion Criteria
- patients with malignant bone disease;
- patients with moderate to severe pain.
Exclusion Criteria
- patients who have received a bisphosphonate within 3 weeks from the signing of informed consent;
- patients receiving concurrent investigational therapy, or who have received investigational therapy within 30 days of the first scheduled day of dosing;
- untreated esophagitis or gastric ulcers;
- recent or pre-scheduled radiotherapy to bone;
- patients who are pregnant or breast-feeding.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 zoledronic acid - 1 ibandronate [Bondronat] -
- Primary Outcome Measures
Name Time Method Pain, as measured by Brief Pain Inventory and analgesic use Week 24
- Secondary Outcome Measures
Name Time Method Skeletal-related events Throughout study Performance score and QoL measures Week 24 AEs and laboratory parameters Throughout study Opioid side effects Throughout study